Article Text

Download PDFPDF

LP-170 Predictors of neuropsychiatric flares In Patients With Systemic Lupus Erythematosus: Results From Five Phase III clinical trials of belimumab
  1. Leonardo Palazzo1,
  2. Julius Lindblom1,
  3. Nursen Cetrez1,
  4. Henri Ala1 and
  5. Ioannis Parodis1,2
  1. 1Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Sweden
  2. 2Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Sweden


Background Belimumab has shown ability to reduce flare rates in systemic lupus erythematosus (SLE), but little is known about its potential benefits in neuropsychiatric (NP)SLE. We investigated predictors of NP flares in SLE patients under standard therapy with or without add-on belimumab.

Methods Data from five clinical trials of belimumab in SLE (BLISS-52, BLISS-76, BLISS-NEA, BLISS-SC, EMBRACE) were utilised (N=3638). Flares were defined using the British Isles Lupus Assessment Group (BILAG) activity index. Predictors of flares were investigated throughout a 52-week follow-up using univariable and multivariable Cox regression. A subgroup analysis in patients with baseline NP BILAG E was performed to determine predictors of de novo NP flare. Organ damage was assessed using the SLICC/ACR Damage Index (SDI).

Results In total, 105 (2.9%) NP flares were documented. In multivariable analysis, male sex (HR: 2.37; 95% CI: 1.31–4.28; p=0.004), baseline NP BILAG B-D (HR: 5.91; 95% CI: 3.86–9.06; p<0.001), and high baseline SDI score (HR: 1.35; 95% CI: 1.21–1.50; p<0.001) were highly associated with NP flare development. Belimumab use yielded no clear protection. In a separate analysis of SDI domains, the NP domain (HR: 3.25; 95% CI: 2.72–3.88; p<0.001) was the strongest predictor of NP flare, with cognitive impairment (HR: 14.29; 95% CI: 9.22–22.14; p<0.001), transverse myelitis (HR: 21.89; 95% CI: 5.40–88.72; p<0.001), and neuropathy (HR: 8.87; 95% CI: 5.59–14.09; p<0.001) mainly driving this association. In the subgroup analysis of the NP BILAG E population, male sex was the strongest predictor of de novo NP flare (HR: 3.26; 95% CI: 1.51–7.04; p=0.003).

Conclusions Current or former NPSLE activity and established organ damage in the NP domain at baseline were the strongest predictors of NP flare. Whether belimumab treatment protects against NP events remains unclear.

  • Systemic lupus erythematosus
  • Neuropsychiatric flares
  • Belimumab

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.